Related references
Note: Only part of the references are listed.Emerging RNA Therapeutics to Lower Blood Levels of Lp(a) JACC Focus Seminar 2/4
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Is Small Dense LDL a Highly Atherogenic Lipid or a Biomarker of Pro-Atherogenic Phenotype?
Jeffrey W. Meeusen
CLINICAL CHEMISTRY (2021)
Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy
Anne Langsted et al.
CURRENT ATHEROSCLEROSIS REPORTS (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus
Benjamin Burggraaf et al.
DIABETES OBESITY & METABOLISM (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects
Marja-Riitta Taskinen et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia
Massimiliano Ruscica et al.
PHARMACOLOGICAL RESEARCH (2020)
ESC position paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome
Heinz Drexel et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2020)
Causes and Consequences of Hypertriglyceridemia
Chris J. Packard et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Efficacy and tolerability of alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study
Deborah R. Leitner et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Apolipoprotein C-II: the re-emergence of a forgotten factor
Anna Wolska et al.
CURRENT OPINION IN LIPIDOLOGY (2020)
Lipids and Lipoproteins in 2020
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Nam Hoon Kim et al.
DIABETES & METABOLISM JOURNAL (2020)
Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study
Tim Hollstein et al.
VASCULAR PHARMACOLOGY (2019)
The Chylomicronemia Syndrome Is Most Often Multifactorial A Narrative Review of Causes and Treatment
Alan Chait et al.
ANNALS OF INTERNAL MEDICINE (2019)
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
Kausik K. Ray et al.
CARDIOVASCULAR DIABETOLOGY (2019)
LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study
Guenther Silbernagel et al.
ATHEROSCLEROSIS (2019)
Phlebotomy tube interference with nuclear magnetic resonance (NMR) lipoprotein subclass analysis
Laura L. Needham et al.
CLINICA CHIMICA ACTA (2019)
The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption
Guenther Silbernagel et al.
JOURNAL OF LIPID RESEARCH (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
Robert R. Henry et al.
DIABETES OBESITY & METABOLISM (2018)
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies A Mendelian Randomization Analysis
Stephen Burgess et al.
JAMA CARDIOLOGY (2018)
Impact of Lipids on Cardiovascular Health JACC Health Promotion Series
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Assessment of the Validity and Reproducibility of a Novel Standardized Test Meal for the Study of Postprandial Triacylglycerol Concentrations
Nikolaos Tentolouris et al.
LIPIDS (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High-Density Lipoprotein Subclasses, Coronary Artery Disease, and Cardiovascular Mortality
Guenther Silbernagel et al.
CLINICAL CHEMISTRY (2017)
ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen
Natalia A. Rocha et al.
CURRENT ATHEROSCLEROSIS REPORTS (2017)
HDL cholesterol: reappraisal of its clinical relevance
Winfried Maerz et al.
CLINICAL RESEARCH IN CARDIOLOGY (2017)
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
Borge G. Nordestgaard
CIRCULATION RESEARCH (2016)
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
Borge G. Nordestgaard et al.
JOURNAL OF LIPID RESEARCH (2016)
Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
Michael J. Koren et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease The Atherosclerosis Risk in Communities ( ARIC) Study
Ron C. Hoogeveen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease
Paul T. Williams et al.
ATHEROSCLEROSIS (2014)
Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
Uchechukwu K. Sampson et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
Lipids and lipoproteins in patients with type 2 diabetes
RM Krauss
DIABETES CARE (2004)
Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease
S Koba et al.
AMERICAN HEART JOURNAL (2002)
Share Paper
